Garraffo, R. | IICIMED

Garraffo, R.

Publications

Autres publications scientifiques

PS29

J Antimicrob Chemother 2023, 78(3):853-854.

Comment on Population pharmacokinetics of the rilpivirine long-acting formulation after intramuscular dosing in healthy subjects and people living with HIV.

Benaboud, S. | Solas, C. | Bouchet, S. | Grégoire, M. | Lemaitre, F. | Venisse, N. | Lê, M. | Muret, P. | Parant, F. | Néant, N. | Boujaafar, S. | Lagoutte-Renosi, J. | Garraffo, R. | Peytavin, G.

https://doi.org/10.1093/jac/dkad009

PS26

Br J Clin Pharmacol 2023.

Therapeutic drug monitoring and virological response at week 48 in a cohort ofHIV-1-infected patients switching to dolutegravir/rilpivirine dual maintenance therapy (ANRS-MIE-BIRIDER Study). 

Lemaitre, F. | Lagoutte-Renosi, J. | Gagnieu, M.-C. | Parant, F. | Venisse, N. | Grégoire, M. | Bouchet, S. | Garraffo, R. | Lê, M.-P. | Muret, P. | Comets, E. | Solas, C. | Peytavin, G.

https://doi.org/10.1111/bcp.15890

PS11

J. Antimicrob. Chemother. 2023, 78, 853-854.

Comment on Population pharmacokinetics of the rilpivirine long-acting formulation after intramuscular dosing in healthy subjects and people living with HIV.

Benaboud, S. | Solas, C. | Bouchet, S. | Gregoire, M. | Lemaitre, F. | Venisse, N. | Lê, M. | Muret, P. | Parant, F. | Néant, N. | Boujaafar, S. | Lagoutte-Renosi, J. | Garraffo, R. | Peytavin, G.

https://doi.org/10.1093/jac/dkad009

Brevets

Thèse